nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—OPRD1—coronary artery disease	0.346	1	CbGaD
Naltrexone—UGT1A1—Ezetimibe—coronary artery disease	0.0503	0.121	CbGbCtD
Naltrexone—UGT1A1—Simvastatin—coronary artery disease	0.0467	0.113	CbGbCtD
Naltrexone—UGT1A1—Lovastatin—coronary artery disease	0.0457	0.11	CbGbCtD
Naltrexone—UGT1A1—Atorvastatin—coronary artery disease	0.0417	0.1	CbGbCtD
Naltrexone—UGT1A1—Losartan—coronary artery disease	0.0381	0.0919	CbGbCtD
Naltrexone—ABCB1—Ticagrelor—coronary artery disease	0.025	0.0604	CbGbCtD
Naltrexone—ABCB1—Perindopril—coronary artery disease	0.0155	0.0373	CbGbCtD
Naltrexone—ABCB1—Clopidogrel—coronary artery disease	0.0155	0.0373	CbGbCtD
Naltrexone—ABCB1—Pitavastatin—coronary artery disease	0.0135	0.0326	CbGbCtD
Naltrexone—ABCB1—Telmisartan—coronary artery disease	0.0135	0.0326	CbGbCtD
Naltrexone—ABCB1—Lisinopril—coronary artery disease	0.0128	0.0309	CbGbCtD
Naltrexone—ABCB1—Enalapril—coronary artery disease	0.0128	0.0309	CbGbCtD
Naltrexone—ABCB1—Timolol—coronary artery disease	0.0109	0.0263	CbGbCtD
Naltrexone—ABCB1—Ezetimibe—coronary artery disease	0.00997	0.024	CbGbCtD
Naltrexone—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00972	0.0234	CbGbCtD
Naltrexone—ABCB1—Captopril—coronary artery disease	0.0096	0.0232	CbGbCtD
Naltrexone—ABCB1—Simvastatin—coronary artery disease	0.00927	0.0224	CbGbCtD
Naltrexone—ABCB1—Lovastatin—coronary artery disease	0.00907	0.0219	CbGbCtD
Naltrexone—ABCB1—Pravastatin—coronary artery disease	0.00907	0.0219	CbGbCtD
Naltrexone—ABCB1—Atorvastatin—coronary artery disease	0.00826	0.0199	CbGbCtD
Naltrexone—ABCB1—Losartan—coronary artery disease	0.00756	0.0182	CbGbCtD
Naltrexone—Naloxone—CREB1—coronary artery disease	0.000688	0.174	CrCbGaD
Naltrexone—Butorphanol—OPRD1—coronary artery disease	0.000493	0.125	CrCbGaD
Naltrexone—Nalbuphine—OPRD1—coronary artery disease	0.000451	0.114	CrCbGaD
Naltrexone—Oxymorphone—OPRD1—coronary artery disease	0.000368	0.0932	CrCbGaD
Naltrexone—Hydrocodone—OPRD1—coronary artery disease	0.000322	0.0815	CrCbGaD
Naltrexone—Oxycodone—OPRD1—coronary artery disease	0.000293	0.0743	CrCbGaD
Naltrexone—Buprenorphine—OPRD1—coronary artery disease	0.00027	0.0685	CrCbGaD
Naltrexone—Naloxone—OPRD1—coronary artery disease	0.000268	0.068	CrCbGaD
Naltrexone—Hydromorphone—OPRD1—coronary artery disease	0.000266	0.0675	CrCbGaD
Naltrexone—Morphine—OPRD1—coronary artery disease	0.000227	0.0574	CrCbGaD
Naltrexone—Naloxone—ESR1—coronary artery disease	0.000134	0.0339	CrCbGaD
Naltrexone—Buprenorphine—CYP2C19—coronary artery disease	0.000108	0.0274	CrCbGaD
Naltrexone—Naloxone—ALB—coronary artery disease	5.95e-05	0.0151	CrCbGaD
Naltrexone—Abdominal pain—Captopril—coronary artery disease	4.41e-05	0.00027	CcSEcCtD
Naltrexone—Body temperature increased—Captopril—coronary artery disease	4.41e-05	0.00027	CcSEcCtD
Naltrexone—Dizziness—Simvastatin—coronary artery disease	4.4e-05	0.000269	CcSEcCtD
Naltrexone—Rash—Ezetimibe—coronary artery disease	4.4e-05	0.000269	CcSEcCtD
Naltrexone—Dermatitis—Ezetimibe—coronary artery disease	4.39e-05	0.000269	CcSEcCtD
Naltrexone—Confusional state—Ramipril—coronary artery disease	4.39e-05	0.000269	CcSEcCtD
Naltrexone—Discomfort—Timolol—coronary artery disease	4.39e-05	0.000269	CcSEcCtD
Naltrexone—Asthenia—Niacin—coronary artery disease	4.38e-05	0.000268	CcSEcCtD
Naltrexone—Fatigue—Losartan—coronary artery disease	4.38e-05	0.000268	CcSEcCtD
Naltrexone—Headache—Ezetimibe—coronary artery disease	4.37e-05	0.000267	CcSEcCtD
Naltrexone—Malaise—Lisinopril—coronary artery disease	4.36e-05	0.000267	CcSEcCtD
Naltrexone—Oedema—Ramipril—coronary artery disease	4.35e-05	0.000267	CcSEcCtD
Naltrexone—Anaphylactic shock—Ramipril—coronary artery disease	4.35e-05	0.000267	CcSEcCtD
Naltrexone—Dry mouth—Timolol—coronary artery disease	4.34e-05	0.000266	CcSEcCtD
Naltrexone—Constipation—Losartan—coronary artery disease	4.34e-05	0.000266	CcSEcCtD
Naltrexone—Pain—Losartan—coronary artery disease	4.34e-05	0.000266	CcSEcCtD
Naltrexone—Syncope—Lisinopril—coronary artery disease	4.34e-05	0.000266	CcSEcCtD
Naltrexone—Vomiting—Eplerenone—coronary artery disease	4.34e-05	0.000266	CcSEcCtD
Naltrexone—Feeling abnormal—Furosemide—coronary artery disease	4.34e-05	0.000265	CcSEcCtD
Naltrexone—Nausea—Fenofibrate—coronary artery disease	4.32e-05	0.000265	CcSEcCtD
Naltrexone—Pruritus—Niacin—coronary artery disease	4.32e-05	0.000264	CcSEcCtD
Naltrexone—Asthenia—Pravastatin—coronary artery disease	4.31e-05	0.000264	CcSEcCtD
Naltrexone—Gastrointestinal pain—Furosemide—coronary artery disease	4.3e-05	0.000263	CcSEcCtD
Naltrexone—Rash—Eplerenone—coronary artery disease	4.3e-05	0.000263	CcSEcCtD
Naltrexone—Urticaria—Perindopril—coronary artery disease	4.3e-05	0.000263	CcSEcCtD
Naltrexone—Hypersensitivity—Trandolapril—coronary artery disease	4.3e-05	0.000263	CcSEcCtD
Naltrexone—Dermatitis—Eplerenone—coronary artery disease	4.3e-05	0.000263	CcSEcCtD
Naltrexone—Diarrhoea—Valsartan—coronary artery disease	4.3e-05	0.000263	CcSEcCtD
Naltrexone—Confusional state—Timolol—coronary artery disease	4.29e-05	0.000263	CcSEcCtD
Naltrexone—Shock—Ramipril—coronary artery disease	4.28e-05	0.000262	CcSEcCtD
Naltrexone—Hypersensitivity—Enalapril—coronary artery disease	4.28e-05	0.000262	CcSEcCtD
Naltrexone—Body temperature increased—Perindopril—coronary artery disease	4.28e-05	0.000262	CcSEcCtD
Naltrexone—Abdominal pain—Perindopril—coronary artery disease	4.28e-05	0.000262	CcSEcCtD
Naltrexone—Palpitations—Lisinopril—coronary artery disease	4.28e-05	0.000262	CcSEcCtD
Naltrexone—Diarrhoea—Olmesartan—coronary artery disease	4.28e-05	0.000262	CcSEcCtD
Naltrexone—Headache—Eplerenone—coronary artery disease	4.27e-05	0.000262	CcSEcCtD
Naltrexone—Nervous system disorder—Ramipril—coronary artery disease	4.27e-05	0.000261	CcSEcCtD
Naltrexone—Oedema—Timolol—coronary artery disease	4.26e-05	0.000261	CcSEcCtD
Naltrexone—Anaphylactic shock—Timolol—coronary artery disease	4.26e-05	0.000261	CcSEcCtD
Naltrexone—Pruritus—Pravastatin—coronary artery disease	4.25e-05	0.00026	CcSEcCtD
Naltrexone—Loss of consciousness—Lisinopril—coronary artery disease	4.25e-05	0.00026	CcSEcCtD
Naltrexone—Nausea—Clopidogrel—coronary artery disease	4.25e-05	0.00026	CcSEcCtD
Naltrexone—Tachycardia—Ramipril—coronary artery disease	4.25e-05	0.00026	CcSEcCtD
Naltrexone—Skin disorder—Ramipril—coronary artery disease	4.23e-05	0.000259	CcSEcCtD
Naltrexone—Infection—Timolol—coronary artery disease	4.23e-05	0.000259	CcSEcCtD
Naltrexone—Vomiting—Simvastatin—coronary artery disease	4.23e-05	0.000259	CcSEcCtD
Naltrexone—Hypersensitivity—Telmisartan—coronary artery disease	4.22e-05	0.000259	CcSEcCtD
Naltrexone—Cough—Lisinopril—coronary artery disease	4.22e-05	0.000258	CcSEcCtD
Naltrexone—Nausea—Lovastatin—coronary artery disease	4.22e-05	0.000258	CcSEcCtD
Naltrexone—Hyperhidrosis—Ramipril—coronary artery disease	4.21e-05	0.000258	CcSEcCtD
Naltrexone—Rash—Simvastatin—coronary artery disease	4.19e-05	0.000257	CcSEcCtD
Naltrexone—Dermatitis—Simvastatin—coronary artery disease	4.19e-05	0.000256	CcSEcCtD
Naltrexone—Asthenia—Trandolapril—coronary artery disease	4.19e-05	0.000256	CcSEcCtD
Naltrexone—Shock—Timolol—coronary artery disease	4.19e-05	0.000256	CcSEcCtD
Naltrexone—Feeling abnormal—Losartan—coronary artery disease	4.18e-05	0.000256	CcSEcCtD
Naltrexone—Urticaria—Furosemide—coronary artery disease	4.18e-05	0.000256	CcSEcCtD
Naltrexone—Diarrhoea—Niacin—coronary artery disease	4.18e-05	0.000256	CcSEcCtD
Naltrexone—Nervous system disorder—Timolol—coronary artery disease	4.17e-05	0.000256	CcSEcCtD
Naltrexone—Asthenia—Enalapril—coronary artery disease	4.17e-05	0.000255	CcSEcCtD
Naltrexone—Headache—Simvastatin—coronary artery disease	4.17e-05	0.000255	CcSEcCtD
Naltrexone—Body temperature increased—Furosemide—coronary artery disease	4.16e-05	0.000255	CcSEcCtD
Naltrexone—Abdominal pain—Furosemide—coronary artery disease	4.16e-05	0.000255	CcSEcCtD
Naltrexone—Gastrointestinal pain—Losartan—coronary artery disease	4.15e-05	0.000254	CcSEcCtD
Naltrexone—Dizziness—Valsartan—coronary artery disease	4.15e-05	0.000254	CcSEcCtD
Naltrexone—Anorexia—Ramipril—coronary artery disease	4.15e-05	0.000254	CcSEcCtD
Naltrexone—Nausea—Ezetimibe—coronary artery disease	4.14e-05	0.000253	CcSEcCtD
Naltrexone—Skin disorder—Timolol—coronary artery disease	4.13e-05	0.000253	CcSEcCtD
Naltrexone—Dizziness—Olmesartan—coronary artery disease	4.13e-05	0.000253	CcSEcCtD
Naltrexone—Pruritus—Trandolapril—coronary artery disease	4.13e-05	0.000253	CcSEcCtD
Naltrexone—Myalgia—Lisinopril—coronary artery disease	4.12e-05	0.000252	CcSEcCtD
Naltrexone—Chest pain—Lisinopril—coronary artery disease	4.12e-05	0.000252	CcSEcCtD
Naltrexone—Arthralgia—Lisinopril—coronary artery disease	4.12e-05	0.000252	CcSEcCtD
Naltrexone—Hyperhidrosis—Timolol—coronary artery disease	4.12e-05	0.000252	CcSEcCtD
Naltrexone—Asthenia—Telmisartan—coronary artery disease	4.11e-05	0.000252	CcSEcCtD
Naltrexone—Pruritus—Enalapril—coronary artery disease	4.11e-05	0.000252	CcSEcCtD
Naltrexone—Diarrhoea—Pravastatin—coronary artery disease	4.11e-05	0.000252	CcSEcCtD
Naltrexone—Anxiety—Lisinopril—coronary artery disease	4.11e-05	0.000251	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	4.09e-05	0.00025	CcSEcCtD
Naltrexone—Discomfort—Lisinopril—coronary artery disease	4.07e-05	0.000249	CcSEcCtD
Naltrexone—Anorexia—Timolol—coronary artery disease	4.06e-05	0.000248	CcSEcCtD
Naltrexone—Pruritus—Telmisartan—coronary artery disease	4.06e-05	0.000248	CcSEcCtD
Naltrexone—Nausea—Eplerenone—coronary artery disease	4.05e-05	0.000248	CcSEcCtD
Naltrexone—Dizziness—Niacin—coronary artery disease	4.04e-05	0.000247	CcSEcCtD
Naltrexone—Urticaria—Losartan—coronary artery disease	4.03e-05	0.000247	CcSEcCtD
Naltrexone—Dry mouth—Lisinopril—coronary artery disease	4.03e-05	0.000247	CcSEcCtD
Naltrexone—Abdominal pain—Losartan—coronary artery disease	4.01e-05	0.000246	CcSEcCtD
Naltrexone—Body temperature increased—Losartan—coronary artery disease	4.01e-05	0.000246	CcSEcCtD
Naltrexone—Asthenia—Captopril—coronary artery disease	4e-05	0.000245	CcSEcCtD
Naltrexone—Diarrhoea—Trandolapril—coronary artery disease	3.99e-05	0.000244	CcSEcCtD
Naltrexone—Vomiting—Valsartan—coronary artery disease	3.99e-05	0.000244	CcSEcCtD
Naltrexone—Confusional state—Lisinopril—coronary artery disease	3.98e-05	0.000244	CcSEcCtD
Naltrexone—Diarrhoea—Enalapril—coronary artery disease	3.98e-05	0.000243	CcSEcCtD
Naltrexone—Dizziness—Pravastatin—coronary artery disease	3.97e-05	0.000243	CcSEcCtD
Naltrexone—Vomiting—Olmesartan—coronary artery disease	3.97e-05	0.000243	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Ramipril—coronary artery disease	3.97e-05	0.000243	CcSEcCtD
Naltrexone—Rash—Valsartan—coronary artery disease	3.96e-05	0.000242	CcSEcCtD
Naltrexone—Dermatitis—Valsartan—coronary artery disease	3.96e-05	0.000242	CcSEcCtD
Naltrexone—Nausea—Simvastatin—coronary artery disease	3.95e-05	0.000242	CcSEcCtD
Naltrexone—Anaphylactic shock—Lisinopril—coronary artery disease	3.95e-05	0.000242	CcSEcCtD
Naltrexone—Oedema—Lisinopril—coronary artery disease	3.95e-05	0.000242	CcSEcCtD
Naltrexone—Pruritus—Captopril—coronary artery disease	3.95e-05	0.000241	CcSEcCtD
Naltrexone—Rash—Olmesartan—coronary artery disease	3.94e-05	0.000241	CcSEcCtD
Naltrexone—Insomnia—Ramipril—coronary artery disease	3.94e-05	0.000241	CcSEcCtD
Naltrexone—Dermatitis—Olmesartan—coronary artery disease	3.94e-05	0.000241	CcSEcCtD
Naltrexone—Headache—Valsartan—coronary artery disease	3.93e-05	0.000241	CcSEcCtD
Naltrexone—Diarrhoea—Telmisartan—coronary artery disease	3.92e-05	0.00024	CcSEcCtD
Naltrexone—Infection—Lisinopril—coronary artery disease	3.92e-05	0.00024	CcSEcCtD
Naltrexone—Headache—Olmesartan—coronary artery disease	3.91e-05	0.00024	CcSEcCtD
Naltrexone—Paraesthesia—Ramipril—coronary artery disease	3.91e-05	0.000239	CcSEcCtD
Naltrexone—Shock—Lisinopril—coronary artery disease	3.89e-05	0.000238	CcSEcCtD
Naltrexone—Asthenia—Perindopril—coronary artery disease	3.88e-05	0.000238	CcSEcCtD
Naltrexone—Dyspnoea—Ramipril—coronary artery disease	3.88e-05	0.000238	CcSEcCtD
Naltrexone—Vomiting—Niacin—coronary artery disease	3.88e-05	0.000238	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Timolol—coronary artery disease	3.88e-05	0.000237	CcSEcCtD
Naltrexone—Hypersensitivity—Furosemide—coronary artery disease	3.88e-05	0.000237	CcSEcCtD
Naltrexone—Somnolence—Ramipril—coronary artery disease	3.87e-05	0.000237	CcSEcCtD
Naltrexone—Dizziness—Trandolapril—coronary artery disease	3.86e-05	0.000236	CcSEcCtD
Naltrexone—Tachycardia—Lisinopril—coronary artery disease	3.85e-05	0.000236	CcSEcCtD
Naltrexone—Insomnia—Timolol—coronary artery disease	3.85e-05	0.000236	CcSEcCtD
Naltrexone—Rash—Niacin—coronary artery disease	3.85e-05	0.000236	CcSEcCtD
Naltrexone—Dermatitis—Niacin—coronary artery disease	3.85e-05	0.000235	CcSEcCtD
Naltrexone—Dizziness—Enalapril—coronary artery disease	3.84e-05	0.000235	CcSEcCtD
Naltrexone—Skin disorder—Lisinopril—coronary artery disease	3.84e-05	0.000235	CcSEcCtD
Naltrexone—Pruritus—Perindopril—coronary artery disease	3.83e-05	0.000234	CcSEcCtD
Naltrexone—Headache—Niacin—coronary artery disease	3.82e-05	0.000234	CcSEcCtD
Naltrexone—Paraesthesia—Timolol—coronary artery disease	3.82e-05	0.000234	CcSEcCtD
Naltrexone—Vomiting—Pravastatin—coronary artery disease	3.82e-05	0.000234	CcSEcCtD
Naltrexone—Hyperhidrosis—Lisinopril—coronary artery disease	3.82e-05	0.000234	CcSEcCtD
Naltrexone—Diarrhoea—Captopril—coronary artery disease	3.82e-05	0.000234	CcSEcCtD
Naltrexone—Dyspnoea—Timolol—coronary artery disease	3.79e-05	0.000232	CcSEcCtD
Naltrexone—Dizziness—Telmisartan—coronary artery disease	3.79e-05	0.000232	CcSEcCtD
Naltrexone—Rash—Pravastatin—coronary artery disease	3.79e-05	0.000232	CcSEcCtD
Naltrexone—Dermatitis—Pravastatin—coronary artery disease	3.79e-05	0.000232	CcSEcCtD
Naltrexone—Decreased appetite—Ramipril—coronary artery disease	3.79e-05	0.000232	CcSEcCtD
Naltrexone—Somnolence—Timolol—coronary artery disease	3.78e-05	0.000232	CcSEcCtD
Naltrexone—Asthenia—Furosemide—coronary artery disease	3.78e-05	0.000231	CcSEcCtD
Naltrexone—Headache—Pravastatin—coronary artery disease	3.77e-05	0.000231	CcSEcCtD
Naltrexone—Anorexia—Lisinopril—coronary artery disease	3.76e-05	0.00023	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Ramipril—coronary artery disease	3.76e-05	0.00023	CcSEcCtD
Naltrexone—Fatigue—Ramipril—coronary artery disease	3.75e-05	0.00023	CcSEcCtD
Naltrexone—Hypersensitivity—Losartan—coronary artery disease	3.74e-05	0.000229	CcSEcCtD
Naltrexone—Nausea—Valsartan—coronary artery disease	3.73e-05	0.000228	CcSEcCtD
Naltrexone—Pruritus—Furosemide—coronary artery disease	3.72e-05	0.000228	CcSEcCtD
Naltrexone—Constipation—Ramipril—coronary artery disease	3.72e-05	0.000228	CcSEcCtD
Naltrexone—Nausea—Olmesartan—coronary artery disease	3.71e-05	0.000227	CcSEcCtD
Naltrexone—Vomiting—Trandolapril—coronary artery disease	3.71e-05	0.000227	CcSEcCtD
Naltrexone—Diarrhoea—Perindopril—coronary artery disease	3.7e-05	0.000227	CcSEcCtD
Naltrexone—Decreased appetite—Timolol—coronary artery disease	3.7e-05	0.000227	CcSEcCtD
Naltrexone—Vomiting—Enalapril—coronary artery disease	3.7e-05	0.000226	CcSEcCtD
Naltrexone—Dizziness—Captopril—coronary artery disease	3.69e-05	0.000226	CcSEcCtD
Naltrexone—Rash—Trandolapril—coronary artery disease	3.68e-05	0.000225	CcSEcCtD
Naltrexone—Dermatitis—Trandolapril—coronary artery disease	3.68e-05	0.000225	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Timolol—coronary artery disease	3.67e-05	0.000225	CcSEcCtD
Naltrexone—Fatigue—Timolol—coronary artery disease	3.67e-05	0.000225	CcSEcCtD
Naltrexone—Rash—Enalapril—coronary artery disease	3.67e-05	0.000224	CcSEcCtD
Naltrexone—Dermatitis—Enalapril—coronary artery disease	3.66e-05	0.000224	CcSEcCtD
Naltrexone—Headache—Trandolapril—coronary artery disease	3.66e-05	0.000224	CcSEcCtD
Naltrexone—Vomiting—Telmisartan—coronary artery disease	3.65e-05	0.000223	CcSEcCtD
Naltrexone—Asthenia—Losartan—coronary artery disease	3.64e-05	0.000223	CcSEcCtD
Naltrexone—Headache—Enalapril—coronary artery disease	3.64e-05	0.000223	CcSEcCtD
Naltrexone—Pain—Timolol—coronary artery disease	3.64e-05	0.000223	CcSEcCtD
Naltrexone—Nausea—Niacin—coronary artery disease	3.63e-05	0.000222	CcSEcCtD
Naltrexone—Rash—Telmisartan—coronary artery disease	3.62e-05	0.000221	CcSEcCtD
Naltrexone—Dermatitis—Telmisartan—coronary artery disease	3.61e-05	0.000221	CcSEcCtD
Naltrexone—Diarrhoea—Furosemide—coronary artery disease	3.6e-05	0.00022	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Lisinopril—coronary artery disease	3.6e-05	0.00022	CcSEcCtD
Naltrexone—Pruritus—Losartan—coronary artery disease	3.59e-05	0.00022	CcSEcCtD
Naltrexone—Headache—Telmisartan—coronary artery disease	3.59e-05	0.00022	CcSEcCtD
Naltrexone—Feeling abnormal—Ramipril—coronary artery disease	3.59e-05	0.00022	CcSEcCtD
Naltrexone—Dizziness—Perindopril—coronary artery disease	3.58e-05	0.000219	CcSEcCtD
Naltrexone—Insomnia—Lisinopril—coronary artery disease	3.57e-05	0.000219	CcSEcCtD
Naltrexone—Nausea—Pravastatin—coronary artery disease	3.57e-05	0.000219	CcSEcCtD
Naltrexone—Gastrointestinal pain—Ramipril—coronary artery disease	3.56e-05	0.000218	CcSEcCtD
Naltrexone—Paraesthesia—Lisinopril—coronary artery disease	3.55e-05	0.000217	CcSEcCtD
Naltrexone—Vomiting—Captopril—coronary artery disease	3.55e-05	0.000217	CcSEcCtD
Naltrexone—Dyspnoea—Lisinopril—coronary artery disease	3.52e-05	0.000216	CcSEcCtD
Naltrexone—Rash—Captopril—coronary artery disease	3.52e-05	0.000215	CcSEcCtD
Naltrexone—Dermatitis—Captopril—coronary artery disease	3.51e-05	0.000215	CcSEcCtD
Naltrexone—Somnolence—Lisinopril—coronary artery disease	3.51e-05	0.000215	CcSEcCtD
Naltrexone—Feeling abnormal—Timolol—coronary artery disease	3.51e-05	0.000215	CcSEcCtD
Naltrexone—Headache—Captopril—coronary artery disease	3.49e-05	0.000214	CcSEcCtD
Naltrexone—Gastrointestinal pain—Timolol—coronary artery disease	3.48e-05	0.000213	CcSEcCtD
Naltrexone—Dizziness—Furosemide—coronary artery disease	3.48e-05	0.000213	CcSEcCtD
Naltrexone—Diarrhoea—Losartan—coronary artery disease	3.47e-05	0.000213	CcSEcCtD
Naltrexone—Nausea—Trandolapril—coronary artery disease	3.47e-05	0.000212	CcSEcCtD
Naltrexone—Urticaria—Ramipril—coronary artery disease	3.46e-05	0.000212	CcSEcCtD
Naltrexone—Nausea—Enalapril—coronary artery disease	3.45e-05	0.000211	CcSEcCtD
Naltrexone—Vomiting—Perindopril—coronary artery disease	3.44e-05	0.000211	CcSEcCtD
Naltrexone—Abdominal pain—Ramipril—coronary artery disease	3.44e-05	0.000211	CcSEcCtD
Naltrexone—Body temperature increased—Ramipril—coronary artery disease	3.44e-05	0.000211	CcSEcCtD
Naltrexone—Decreased appetite—Lisinopril—coronary artery disease	3.43e-05	0.00021	CcSEcCtD
Naltrexone—Rash—Perindopril—coronary artery disease	3.41e-05	0.000209	CcSEcCtD
Naltrexone—Dermatitis—Perindopril—coronary artery disease	3.41e-05	0.000209	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Lisinopril—coronary artery disease	3.41e-05	0.000209	CcSEcCtD
Naltrexone—Nausea—Telmisartan—coronary artery disease	3.41e-05	0.000208	CcSEcCtD
Naltrexone—Fatigue—Lisinopril—coronary artery disease	3.4e-05	0.000208	CcSEcCtD
Naltrexone—Headache—Perindopril—coronary artery disease	3.39e-05	0.000208	CcSEcCtD
Naltrexone—Urticaria—Timolol—coronary artery disease	3.38e-05	0.000207	CcSEcCtD
Naltrexone—Pain—Lisinopril—coronary artery disease	3.38e-05	0.000207	CcSEcCtD
Naltrexone—Constipation—Lisinopril—coronary artery disease	3.38e-05	0.000207	CcSEcCtD
Naltrexone—Abdominal pain—Timolol—coronary artery disease	3.36e-05	0.000206	CcSEcCtD
Naltrexone—Body temperature increased—Timolol—coronary artery disease	3.36e-05	0.000206	CcSEcCtD
Naltrexone—Dizziness—Losartan—coronary artery disease	3.36e-05	0.000206	CcSEcCtD
Naltrexone—Vomiting—Furosemide—coronary artery disease	3.35e-05	0.000205	CcSEcCtD
Naltrexone—Rash—Furosemide—coronary artery disease	3.32e-05	0.000203	CcSEcCtD
Naltrexone—Dermatitis—Furosemide—coronary artery disease	3.32e-05	0.000203	CcSEcCtD
Naltrexone—Nausea—Captopril—coronary artery disease	3.31e-05	0.000203	CcSEcCtD
Naltrexone—Headache—Furosemide—coronary artery disease	3.3e-05	0.000202	CcSEcCtD
Naltrexone—Feeling abnormal—Lisinopril—coronary artery disease	3.25e-05	0.000199	CcSEcCtD
Naltrexone—Gastrointestinal pain—Lisinopril—coronary artery disease	3.23e-05	0.000198	CcSEcCtD
Naltrexone—Vomiting—Losartan—coronary artery disease	3.23e-05	0.000198	CcSEcCtD
Naltrexone—Nausea—Perindopril—coronary artery disease	3.22e-05	0.000197	CcSEcCtD
Naltrexone—Hypersensitivity—Ramipril—coronary artery disease	3.21e-05	0.000196	CcSEcCtD
Naltrexone—Rash—Losartan—coronary artery disease	3.2e-05	0.000196	CcSEcCtD
Naltrexone—Dermatitis—Losartan—coronary artery disease	3.2e-05	0.000196	CcSEcCtD
Naltrexone—Headache—Losartan—coronary artery disease	3.18e-05	0.000195	CcSEcCtD
Naltrexone—Urticaria—Lisinopril—coronary artery disease	3.14e-05	0.000192	CcSEcCtD
Naltrexone—Hypersensitivity—Timolol—coronary artery disease	3.14e-05	0.000192	CcSEcCtD
Naltrexone—Nausea—Furosemide—coronary artery disease	3.13e-05	0.000191	CcSEcCtD
Naltrexone—Asthenia—Ramipril—coronary artery disease	3.12e-05	0.000191	CcSEcCtD
Naltrexone—Abdominal pain—Lisinopril—coronary artery disease	3.12e-05	0.000191	CcSEcCtD
Naltrexone—Body temperature increased—Lisinopril—coronary artery disease	3.12e-05	0.000191	CcSEcCtD
Naltrexone—Pruritus—Ramipril—coronary artery disease	3.08e-05	0.000189	CcSEcCtD
Naltrexone—Asthenia—Timolol—coronary artery disease	3.05e-05	0.000187	CcSEcCtD
Naltrexone—Nausea—Losartan—coronary artery disease	3.02e-05	0.000185	CcSEcCtD
Naltrexone—Pruritus—Timolol—coronary artery disease	3.01e-05	0.000184	CcSEcCtD
Naltrexone—Diarrhoea—Ramipril—coronary artery disease	2.98e-05	0.000182	CcSEcCtD
Naltrexone—Diarrhoea—Timolol—coronary artery disease	2.91e-05	0.000178	CcSEcCtD
Naltrexone—Hypersensitivity—Lisinopril—coronary artery disease	2.91e-05	0.000178	CcSEcCtD
Naltrexone—Dizziness—Ramipril—coronary artery disease	2.88e-05	0.000176	CcSEcCtD
Naltrexone—Asthenia—Lisinopril—coronary artery disease	2.83e-05	0.000173	CcSEcCtD
Naltrexone—Dizziness—Timolol—coronary artery disease	2.81e-05	0.000172	CcSEcCtD
Naltrexone—Pruritus—Lisinopril—coronary artery disease	2.79e-05	0.000171	CcSEcCtD
Naltrexone—Vomiting—Ramipril—coronary artery disease	2.77e-05	0.000169	CcSEcCtD
Naltrexone—Rash—Ramipril—coronary artery disease	2.75e-05	0.000168	CcSEcCtD
Naltrexone—Dermatitis—Ramipril—coronary artery disease	2.74e-05	0.000168	CcSEcCtD
Naltrexone—Headache—Ramipril—coronary artery disease	2.73e-05	0.000167	CcSEcCtD
Naltrexone—Vomiting—Timolol—coronary artery disease	2.71e-05	0.000166	CcSEcCtD
Naltrexone—Diarrhoea—Lisinopril—coronary artery disease	2.7e-05	0.000165	CcSEcCtD
Naltrexone—Rash—Timolol—coronary artery disease	2.68e-05	0.000164	CcSEcCtD
Naltrexone—Dermatitis—Timolol—coronary artery disease	2.68e-05	0.000164	CcSEcCtD
Naltrexone—Headache—Timolol—coronary artery disease	2.67e-05	0.000163	CcSEcCtD
Naltrexone—Dizziness—Lisinopril—coronary artery disease	2.61e-05	0.00016	CcSEcCtD
Naltrexone—Nausea—Ramipril—coronary artery disease	2.59e-05	0.000158	CcSEcCtD
Naltrexone—Nausea—Timolol—coronary artery disease	2.53e-05	0.000155	CcSEcCtD
Naltrexone—Vomiting—Lisinopril—coronary artery disease	2.51e-05	0.000154	CcSEcCtD
Naltrexone—Rash—Lisinopril—coronary artery disease	2.49e-05	0.000152	CcSEcCtD
Naltrexone—Dermatitis—Lisinopril—coronary artery disease	2.49e-05	0.000152	CcSEcCtD
Naltrexone—Headache—Lisinopril—coronary artery disease	2.47e-05	0.000151	CcSEcCtD
Naltrexone—Nausea—Lisinopril—coronary artery disease	2.35e-05	0.000144	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—APOB—coronary artery disease	7.4e-06	0.000103	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—coronary artery disease	7.33e-06	0.000102	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—coronary artery disease	7.33e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ITGAV—coronary artery disease	7.32e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KNG1—coronary artery disease	7.3e-06	0.000102	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—LPL—coronary artery disease	7.3e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—JAK2—coronary artery disease	7.3e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EDN1—coronary artery disease	7.28e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—POMC—coronary artery disease	7.28e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CREB1—coronary artery disease	7.28e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR2A—coronary artery disease	7.26e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGTR1—coronary artery disease	7.26e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—C3—coronary artery disease	7.25e-06	0.000101	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLA2G2A—coronary artery disease	7.24e-06	0.000101	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA2—coronary artery disease	7.24e-06	0.000101	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX2—coronary artery disease	7.24e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL5—coronary artery disease	7.22e-06	0.000101	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCG5—coronary artery disease	7.15e-06	9.97e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX4—coronary artery disease	7.15e-06	9.97e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HK1—coronary artery disease	7.15e-06	9.97e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SULT1A1—coronary artery disease	7.15e-06	9.97e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPX1—coronary artery disease	7.12e-06	9.93e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL2—coronary artery disease	7.12e-06	9.92e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CSF2—coronary artery disease	7.11e-06	9.92e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGF1—coronary artery disease	7.11e-06	9.92e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6R—coronary artery disease	7.1e-06	9.89e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL10—coronary artery disease	7.09e-06	9.88e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLG—coronary artery disease	7.07e-06	9.86e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HADHA—coronary artery disease	7.07e-06	9.85e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LPL—coronary artery disease	7.06e-06	9.84e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RPS6KB1—coronary artery disease	7e-06	9.76e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MEF2C—coronary artery disease	7e-06	9.76e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTA1—coronary artery disease	6.99e-06	9.74e-05	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—coronary artery disease	6.98e-06	9.73e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CD36—coronary artery disease	6.94e-06	9.67e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIF1A—coronary artery disease	6.92e-06	9.64e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LPA—coronary artery disease	6.91e-06	9.63e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGT—coronary artery disease	6.89e-06	9.6e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRB2—coronary artery disease	6.88e-06	9.59e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPP2CA—coronary artery disease	6.85e-06	9.55e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ITGB3—coronary artery disease	6.82e-06	9.51e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCE—coronary artery disease	6.8e-06	9.47e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—JAK2—coronary artery disease	6.79e-06	9.46e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SOCS1—coronary artery disease	6.78e-06	9.45e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—S100B—coronary artery disease	6.76e-06	9.43e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LEP—coronary artery disease	6.75e-06	9.41e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOE—coronary artery disease	6.75e-06	9.41e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SOCS3—coronary artery disease	6.7e-06	9.33e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLCB3—coronary artery disease	6.69e-06	9.32e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOA1—coronary artery disease	6.67e-06	9.3e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—coronary artery disease	6.66e-06	9.28e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PPP2CA—coronary artery disease	6.63e-06	9.24e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA5—coronary artery disease	6.62e-06	9.23e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KITLG—coronary artery disease	6.62e-06	9.22e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFBR2—coronary artery disease	6.62e-06	9.22e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—coronary artery disease	6.61e-06	9.22e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—coronary artery disease	6.57e-06	9.16e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK14—coronary artery disease	6.57e-06	9.16e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRKCD—coronary artery disease	6.51e-06	9.07e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—P4HB—coronary artery disease	6.49e-06	9.05e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT5A—coronary artery disease	6.47e-06	9.01e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP3—coronary artery disease	6.47e-06	9.01e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ESR1—coronary artery disease	6.45e-06	8.98e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLA2G1B—coronary artery disease	6.37e-06	8.88e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR2A—coronary artery disease	6.37e-06	8.87e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—F2—coronary artery disease	6.37e-06	8.87e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FN1—coronary artery disease	6.37e-06	8.87e-05	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—coronary artery disease	6.36e-06	8.87e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—C3—coronary artery disease	6.36e-06	8.86e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6ST—coronary artery disease	6.34e-06	8.84e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NFKBIA—coronary artery disease	6.29e-06	8.77e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOB—coronary artery disease	6.25e-06	8.71e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AGT—coronary artery disease	6.24e-06	8.7e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—coronary artery disease	6.2e-06	8.64e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—JAK2—coronary artery disease	6.17e-06	8.59e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EDN1—coronary artery disease	6.15e-06	8.57e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOE—coronary artery disease	6.12e-06	8.53e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL5—coronary artery disease	6.1e-06	8.51e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KIT—coronary artery disease	6.09e-06	8.49e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—coronary artery disease	6.06e-06	8.45e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOA1—coronary artery disease	6.05e-06	8.43e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGT—coronary artery disease	6.04e-06	8.42e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF1—coronary artery disease	6.01e-06	8.38e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CSF2—coronary artery disease	6.01e-06	8.38e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—VCAN—coronary artery disease	6.01e-06	8.38e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LPL—coronary artery disease	5.97e-06	8.32e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDOA—coronary artery disease	5.96e-06	8.31e-05	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—APOA1—coronary artery disease	5.92e-06	8.26e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOE—coronary artery disease	5.92e-06	8.25e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LEP—coronary artery disease	5.92e-06	8.25e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MEF2C—coronary artery disease	5.92e-06	8.24e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RPS6KB1—coronary artery disease	5.92e-06	8.24e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOA1—coronary artery disease	5.85e-06	8.16e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GSK3B—coronary artery disease	5.85e-06	8.15e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—POMC—coronary artery disease	5.8e-06	8.08e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—coronary artery disease	5.8e-06	8.08e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CREB1—coronary artery disease	5.8e-06	8.08e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—DCN—coronary artery disease	5.79e-06	8.07e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ITGB3—coronary artery disease	5.76e-06	8.03e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK14—coronary artery disease	5.76e-06	8.03e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL2—coronary artery disease	5.67e-06	7.91e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6R—coronary artery disease	5.66e-06	7.89e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—coronary artery disease	5.65e-06	7.88e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDH2—coronary artery disease	5.63e-06	7.85e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—coronary artery disease	5.63e-06	7.84e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PPP2CA—coronary artery disease	5.6e-06	7.81e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FN1—coronary artery disease	5.58e-06	7.78e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—F2—coronary artery disease	5.58e-06	7.78e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—coronary artery disease	5.58e-06	7.78e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6ST—coronary artery disease	5.56e-06	7.75e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK1—coronary artery disease	5.55e-06	7.74e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFKBIA—coronary artery disease	5.52e-06	7.69e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCD—coronary artery disease	5.5e-06	7.66e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HBA1—coronary artery disease	5.49e-06	7.65e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2C19—coronary artery disease	5.49e-06	7.65e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LIPC—coronary artery disease	5.49e-06	7.65e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3C2A—coronary artery disease	5.49e-06	7.65e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOC3—coronary artery disease	5.45e-06	7.6e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LDLR—coronary artery disease	5.42e-06	7.55e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR2A—coronary artery disease	5.38e-06	7.5e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—C3—coronary artery disease	5.37e-06	7.49e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC9A1—coronary artery disease	5.36e-06	7.46e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—coronary artery disease	5.36e-06	7.46e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KIT—coronary artery disease	5.34e-06	7.45e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—coronary artery disease	5.33e-06	7.43e-05	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—coronary artery disease	5.31e-06	7.39e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SERPINE1—coronary artery disease	5.3e-06	7.38e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CETP—coronary artery disease	5.29e-06	7.38e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GCLC—coronary artery disease	5.29e-06	7.38e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—POMC—coronary artery disease	5.26e-06	7.33e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SDC1—coronary artery disease	5.23e-06	7.3e-05	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—coronary artery disease	5.2e-06	7.24e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGF2—coronary artery disease	5.13e-06	7.15e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GSK3B—coronary artery disease	5.13e-06	7.15e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—coronary artery disease	5.13e-06	7.14e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGT—coronary artery disease	5.11e-06	7.12e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—POMC—coronary artery disease	5.09e-06	7.09e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CREB1—coronary artery disease	5.09e-06	7.09e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—coronary artery disease	5.06e-06	7.05e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOE—coronary artery disease	5e-06	6.97e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LEP—coronary artery disease	5e-06	6.97e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL2—coronary artery disease	4.98e-06	6.94e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6R—coronary artery disease	4.96e-06	6.91e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOA1—coronary artery disease	4.95e-06	6.89e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSMA6—coronary artery disease	4.95e-06	6.89e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSMB5—coronary artery disease	4.95e-06	6.89e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JAK2—coronary artery disease	4.92e-06	6.85e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—coronary artery disease	4.9e-06	6.83e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—coronary artery disease	4.89e-06	6.82e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK14—coronary artery disease	4.87e-06	6.79e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK1—coronary artery disease	4.87e-06	6.79e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CTGF—coronary artery disease	4.83e-06	6.73e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—coronary artery disease	4.82e-06	6.71e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—coronary artery disease	4.79e-06	6.68e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GOT2—coronary artery disease	4.79e-06	6.67e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMGCR—coronary artery disease	4.79e-06	6.67e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—coronary artery disease	4.78e-06	6.66e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—F2—coronary artery disease	4.72e-06	6.58e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FN1—coronary artery disease	4.72e-06	6.58e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6ST—coronary artery disease	4.7e-06	6.55e-05	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—coronary artery disease	4.69e-06	6.54e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFKBIA—coronary artery disease	4.66e-06	6.5e-05	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—coronary artery disease	4.65e-06	6.48e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SERPINE1—coronary artery disease	4.65e-06	6.47e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—coronary artery disease	4.58e-06	6.39e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KIT—coronary artery disease	4.52e-06	6.29e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGF2—coronary artery disease	4.5e-06	6.27e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—coronary artery disease	4.49e-06	6.25e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—coronary artery disease	4.43e-06	6.18e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLCB1—coronary artery disease	4.4e-06	6.14e-05	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—coronary artery disease	4.33e-06	6.04e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GSK3B—coronary artery disease	4.33e-06	6.04e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JAK2—coronary artery disease	4.31e-06	6.01e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—POMC—coronary artery disease	4.3e-06	5.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CREB1—coronary artery disease	4.3e-06	5.99e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—coronary artery disease	4.29e-06	5.98e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCA1—coronary artery disease	4.27e-06	5.95e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—coronary artery disease	4.27e-06	5.95e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—coronary artery disease	4.22e-06	5.89e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL2—coronary artery disease	4.21e-06	5.86e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6R—coronary artery disease	4.19e-06	5.84e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—coronary artery disease	4.19e-06	5.84e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—coronary artery disease	4.18e-06	5.83e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—coronary artery disease	4.13e-06	5.76e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GGT1—coronary artery disease	4.13e-06	5.76e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GOT1—coronary artery disease	4.13e-06	5.76e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK1—coronary artery disease	4.11e-06	5.73e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—coronary artery disease	4.06e-06	5.66e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—coronary artery disease	3.94e-06	5.49e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—coronary artery disease	3.93e-06	5.48e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—coronary artery disease	3.93e-06	5.48e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SERPINE1—coronary artery disease	3.93e-06	5.47e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF2—coronary artery disease	3.8e-06	5.3e-05	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—coronary artery disease	3.8e-06	5.3e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—coronary artery disease	3.77e-06	5.25e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—coronary artery disease	3.75e-06	5.22e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—coronary artery disease	3.74e-06	5.21e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—coronary artery disease	3.71e-06	5.17e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARGC1A—coronary artery disease	3.68e-06	5.13e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—coronary artery disease	3.66e-06	5.11e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—coronary artery disease	3.66e-06	5.1e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—coronary artery disease	3.64e-06	5.08e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JAK2—coronary artery disease	3.64e-06	5.08e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAT—coronary artery disease	3.61e-06	5.04e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—coronary artery disease	3.57e-06	4.98e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—coronary artery disease	3.56e-06	4.96e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOB—coronary artery disease	3.51e-06	4.89e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—coronary artery disease	3.45e-06	4.81e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—coronary artery disease	3.41e-06	4.75e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LPL—coronary artery disease	3.35e-06	4.67e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—coronary artery disease	3.34e-06	4.66e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—coronary artery disease	3.32e-06	4.63e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK1—coronary artery disease	3.28e-06	4.57e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX1—coronary artery disease	3.27e-06	4.55e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—coronary artery disease	3.21e-06	4.48e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—coronary artery disease	3.2e-06	4.45e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—coronary artery disease	3.18e-06	4.44e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CD36—coronary artery disease	3.18e-06	4.43e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—coronary artery disease	3.16e-06	4.41e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPP2CA—coronary artery disease	3.14e-06	4.38e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—coronary artery disease	3.1e-06	4.32e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—coronary artery disease	3.02e-06	4.2e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—coronary artery disease	3.01e-06	4.19e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—coronary artery disease	2.93e-06	4.09e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—coronary artery disease	2.92e-06	4.07e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK1—coronary artery disease	2.88e-06	4.01e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AGT—coronary artery disease	2.86e-06	3.99e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—coronary artery disease	2.85e-06	3.97e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOE—coronary artery disease	2.81e-06	3.91e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA1—coronary artery disease	2.77e-06	3.87e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—coronary artery disease	2.7e-06	3.76e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—coronary artery disease	2.58e-06	3.6e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—coronary artery disease	2.52e-06	3.51e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—coronary artery disease	2.5e-06	3.48e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—coronary artery disease	2.48e-06	3.45e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—coronary artery disease	2.44e-06	3.41e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK1—coronary artery disease	2.43e-06	3.39e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—POMC—coronary artery disease	2.41e-06	3.36e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—coronary artery disease	2.32e-06	3.24e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—coronary artery disease	2.21e-06	3.08e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—coronary artery disease	2.2e-06	3.06e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—coronary artery disease	2.11e-06	2.94e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—coronary artery disease	2.11e-06	2.94e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—coronary artery disease	2.1e-06	2.93e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—coronary artery disease	2.04e-06	2.84e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—coronary artery disease	1.92e-06	2.68e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—coronary artery disease	1.87e-06	2.6e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—coronary artery disease	1.72e-06	2.4e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—coronary artery disease	1.18e-06	1.65e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—coronary artery disease	9.67e-07	1.35e-05	CbGpPWpGaD
